Jubran Hoche
Hollywood, FLNPI 1710174362
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,208 and has fallen 98.5% since, to $18 in 2024.
Across 155 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$684
- Amgen$538
- UCB, Inc.$265
- Teva Pharmaceuticals USA, Inc.$186
- MDD US Operations, LLC$165
- Sanofi$156
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$201%
- Food & beverage$2,88496%
- Education$903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $684 |
| Amgen(2 entities) | 28 | $538 |
| UCB, Inc. | 12 | $265 |
| Teva Pharmaceuticals USA, Inc. | 8 | $186 |
| MDD US Operations, LLC | 7 | $165 |
| Sanofi | 8 | $156 |
| Novartis | 8 | $150 |
| Johnson & Johnson | 2 | $106 |
| Eisai Inc. | 6 | $106 |
| AstraZeneca(2 entities) | 4 | $77 |
| Lundbeck LLC | 3 | $75 |
| Biohaven Pharmaceuticals, Inc. | 5 | $66 |
| Lilly USA, LLC | 4 | $60 |
| Mallinckrodt Enterprises LLC | 2 | $56 |
| Biogen | 3 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Acorda Therapeutics, Inc | 2 | $42 |
| Argenx US, Inc. | 2 | $40 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $14 |
| SK Life Science, Inc. | 1 | $13 |
| Lupin Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 78 | $1,628 |
| Gabapentin | 41 | $739 |
| Risperidone | 16 | $718 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 20 | $612 |
| RivastigmineRivastigmine Tartrate | 16 | $600 |
| Levetiracetam | 15 | $549 |
| Topiramate | 26 | $346 |
| Duloxetine Hcl | 17 | $336 |
| Amitriptyline Hcl | 15 | $206 |
| Sertraline Hcl | 25 | $178 |
| Nortriptyline Hcl | 11 | $172 |
| Bupropion XlBupropion Hcl | 12 | $150 |
| Meloxicam | 17 | $86 |
| Alprazolam | 15 | $79 |
| Atorvastatin Calcium | 15 | $77 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.